Trial Profile
A Randomized, Open-Label, Two-arm, Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Dacarbazine
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 26 Nov 2019 Status changed from active, no longer recruiting to completed.
- 01 Oct 2019 Planned End Date changed from 5 Nov 2019 to 31 Oct 2019.
- 15 Feb 2018 Planned End Date changed from 30 Apr 2019 to 5 Nov 2019.